Stocktoria
SeaStar Medical Holding Corp ICU
SeaStar Medical Holding Corp (ICU) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.2M at a -984.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ICU | SeaStar Medical Holding Corp | 3/9 | — | — | — |
| PETV | PetVivo Holdings, Inc. | 3/9 | — | — | — |
| EMED | Electromedical Technologies, Inc | 4/9 | — | — | — |
| SINT | Sintx Technologies, Inc. | 2/9 | — | — | — |
| EBRCZ | EBR Systems, Inc. | 2/9 | -12.31 | — | — |
| CODX | Co-Diagnostics, Inc. | 1/9 | -16.26 | — | — |
| LYRA | Lyra Therapeutics, Inc. | 2/9 | — | — | — |
About SeaStar Medical Holding Corp
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
FAQ
Is ICU financially healthy?
SeaStar Medical Holding Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does ICU pay a dividend?
No, SeaStar Medical Holding Corp does not currently pay a dividend.
How profitable is ICU?
In FY2025, SeaStar Medical Holding Corp had a net margin of -984.6% and a return on equity of -116.6%.
What is the analyst price target for ICU?
The average Wall-Street price target for SeaStar Medical Holding Corp is $10.00, about 197.6% above the recent price, from 2 analysts.
Is ICU a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SeaStar Medical Holding Corp: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.